Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06095115 · ClinicalTrials.gov registry record · Phase 3
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 684
- Enrollment target
- 20
- Study locations
NCT06095115: Active Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
NCT06095115 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 684 participants, above the 401-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06095115, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 684 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Primary Outcome
IGA assesses participant's plaque psoriasis.Lesions were graded for induration,erythema and scaling, each using 5 point scale.Induration: 0=no evidence of plaque elevation,1=minimal plaque elevation,=0.25 millimeters(mm);2=mild plaque elevation,=0.5mm;3=moderate plaque elevation,=0.75 mm; 4=severe plaque elevation, greater than(\>)1 mm; Erythema:0=no evidence of erythema, hyperpigmentation may be present,1=faint erythema,2=light red coloration,3=moderate red coloration,4=bright red coloration; S
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-77242113
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Center for Dermatology Clinical Research - Fremont
- Integrative Skin Science and Research - Sacramento
- Rady Childrens Hospital San Diego - San Diego
- Southern California Dermatology - Santa Ana
- Clinical Science Institute - Santa Monica
Florida
- Bioclinical Research Alliance Inc. - Miami
- Ziaderm Research LLC - North Miami Beach
- Forcare Clinical Research Inc - Tampa
Illinois
- Arlington Dermatology - Rolling Meadows
- Northshore Medical Group - Skokie
- Dundee Dermatology - West Dundee
Indiana
- Dawes Fretzin Clinical Research Group LLC - Indianapolis
- Indiana Clinical Trial Center - Plainfield
Arizona
- Medical Dermatology Specialists - Phoenix
Arkansas
- Johnson Dermatology - Fort Smith
Georgia
- Skin Care Physicians of Georgia - Macon
Kentucky
- Qualmedica Research - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2023-10-12 |
| Est. Completion | 2027-04-06 |
| Phase | Phase 3 |
What the registry record for NCT06095115 still lists
NCT06095115 is an interventional study that assigns participants to a tested intervention. The registered 684 participants enrollment target is mid-sized for trials with a published cap, above the 401-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (71% higher).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06095115 names 20 study sites across 10 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06095115 about?
NCT06095115 is a clinical study titled "A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis". The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT06095115?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 684 participants. The study started on 2023-10-12. Estimated completion is 2027-04-06.
What conditions does trial NCT06095115 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06095115?
The interventions under investigation include: Placebo (DRUG), JNJ-77242113 (DRUG).
Who is sponsoring clinical trial NCT06095115?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06095115 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06095115's enrollment target sits among peer trials
684 11th of 45 higher than 35 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06795087 · 684 participants
Discharge Medication Use Post-Operatively in GU Cancer Patients
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI